Search results
1 Beaten-Down S&P 500 Dividend Stock to Buy in June and Hold For a Decade or Longer
Motley Fool via Yahoo Finance· 7 hours agoIf you've been on the sidelines, now could be a great time to buy the stock. Shares of Pfizer have...
Pfizer's Options Frenzy: What You Need to Know - Pfizer (NYSE:PFE)
Benzinga· 5 days agoInsights into Volume & Open Interest Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Pfizer ...
3 Dividend Stocks You May Want To Double Down On
Benzinga via Yahoo Finance· 2 hours agoSometimes, misunderstood stocks benefit investors. Savvy investors can capitalize when a stock is incorrectly perceived as weak during a recession....
Pfizer says tweaked COVID-19 shots boost omicron protection
KRGV Rio Grande Valley· 5 days agoPfizer announced Saturday that tweaking its COVID-19 vaccine to better target the omicron variant is...
Moderna wins FDA approval for RSV vaccine
BioPharma Dive via Yahoo Finance· 4 days agoThe OK for mResvia adds another option for preventing RSV-related disease in older adults, one year after the agency cleared shots from GSK and Pfizer.
COVID Shot After Acute Coronary Syndrome Might Not Prevent Further Events
MedPage Today· 4 days agoVaccination for COVID-19 after an acute coronary syndrome (ACS) event was not associated with better...
If You Can Only Buy One Value Stock in May, It Better Be One of These 3 Names
InvestorPlace via Yahoo Finance· 6 days agoEveryone loves discounts and that’s essentially what value stocks to buy represent. The difference,...
Pfizer (PFE) Up 1.8% Since Last Earnings Report: Can It Continue?
Zacks via Yahoo Finance· 4 days agoQ1 Earnings & Sales Top, EPS Guidance Raised Pfizer’s first-quarter results were strong as it beat...
Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data
Reuters via AOL· 4 days agoPfizer said it expects its cancer drug Lorbrena to top $1 billion in annual sales by 2030 on the...
Pfizer says its its lung cancer drug Lorbrena could be a $1 billion blockbuster
Quartz· 4 days agoAccording to the data, 61% of patients taking Lorbrena had no disease progression after five years,...